Q-omics provides the consensus-scored PRR34 profile across patient tissues and cancer cell-line models. PRR34 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PRR34 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, PRR34 RNA expression shows 17,653 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, and UVM as cancer lineages where PRR34 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRR34 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRR34 survival associations across molecular data types. PRR34 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRR34 RNA expression–survival associations across cancer types. High PRR34 expression shows unfavorable associations in UVM, LAML and ACC, but favorable associations in HNSC, BRCA and LUSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for PRR34 RNA expression.
This table summarizes PRR34 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PRR34. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRR34 shows lower tumor expression in UCEC, BLCA and KIRP and higher tumor expression in HNSC, KIRC and LIHC. The HNSC box plot shows higher PRR34 RNA expression in tumor versus normal tissue (log2 FC = +0.410, t-test p < 0.001).
This table shows molecular features associated with PRR34 in patient tissues and cancer cell lines. In patient samples, PRR34 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRR34 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE.
